HRP20030833B1 - Liquid pharmaceutical composition - Google Patents

Liquid pharmaceutical composition

Info

Publication number
HRP20030833B1
HRP20030833B1 HR20030833A HRP20030833A HRP20030833B1 HR P20030833 B1 HRP20030833 B1 HR P20030833B1 HR 20030833 A HR20030833 A HR 20030833A HR P20030833 A HRP20030833 A HR P20030833A HR P20030833 B1 HRP20030833 B1 HR P20030833B1
Authority
HR
Croatia
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
composition
polyhydric alcohols
volume
Prior art date
Application number
HR20030833A
Other languages
English (en)
Croatian (hr)
Inventor
Mahesh Kulkarni Neema
Schneider Michael
Bernard Silbering Steven
Richard Meyer-Wonnay Hans
Sanii-Yahyai Nahid
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030833(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of HRP20030833A2 publication Critical patent/HRP20030833A2/hr
Publication of HRP20030833B1 publication Critical patent/HRP20030833B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
HR20030833A 2001-05-25 2003-10-14 Liquid pharmaceutical composition HRP20030833B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29383201P 2001-05-25 2001-05-25
US34373301P 2001-10-25 2001-10-25
PCT/IB2002/001500 WO2002094220A1 (fr) 2001-05-25 2002-04-29 Composition pharmaceutique liquide

Publications (2)

Publication Number Publication Date
HRP20030833A2 HRP20030833A2 (en) 2004-08-31
HRP20030833B1 true HRP20030833B1 (en) 2007-04-30

Family

ID=26968180

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030833A HRP20030833B1 (en) 2001-05-25 2003-10-14 Liquid pharmaceutical composition

Country Status (44)

Country Link
US (2) US20020198261A1 (fr)
EP (1) EP1395242B1 (fr)
JP (1) JP2004534764A (fr)
KR (1) KR100582963B1 (fr)
CN (1) CN100346779C (fr)
AP (1) AP1815A (fr)
AR (1) AR033922A1 (fr)
AT (1) ATE334656T1 (fr)
AU (1) AU2002258026B2 (fr)
BG (1) BG108376A (fr)
BR (1) BR0209973A (fr)
CA (1) CA2446574C (fr)
CR (1) CR7150A (fr)
CY (1) CY1105147T1 (fr)
CZ (1) CZ299755B6 (fr)
DE (1) DE60213592T2 (fr)
DK (1) DK1395242T3 (fr)
DO (1) DOP2002000403A (fr)
EA (1) EA008087B1 (fr)
EE (1) EE200300587A (fr)
EG (1) EG24078A (fr)
ES (1) ES2265040T3 (fr)
GE (1) GEP20053620B (fr)
HK (1) HK1062646A1 (fr)
HR (1) HRP20030833B1 (fr)
HU (1) HUP0401366A2 (fr)
IL (1) IL158359A0 (fr)
IS (1) IS2428B (fr)
MA (1) MA27026A1 (fr)
MX (1) MXPA03009392A (fr)
MY (1) MY128615A (fr)
NO (1) NO20035200L (fr)
NZ (1) NZ529173A (fr)
OA (1) OA12604A (fr)
PA (1) PA8545901A1 (fr)
PE (1) PE20030087A1 (fr)
PL (1) PL366384A1 (fr)
PT (1) PT1395242E (fr)
RS (1) RS87203A (fr)
SI (1) SI1395242T1 (fr)
SK (1) SK286227B6 (fr)
SV (1) SV2003001053A (fr)
WO (1) WO2002094220A1 (fr)
ZA (1) ZA200308393B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9710536A (pt) 1996-07-24 1999-08-17 Warner Lambert Co Isobutilgaba e seus derivados para o tratamento da dor
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
BR0313432A (pt) * 2002-08-15 2005-07-12 Pfizer Uso terapêutico de aminoácidos bicìclicos ou tricìclicos fundidos
CA2451267A1 (fr) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
JP2006513257A (ja) * 2002-12-13 2006-04-20 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 線維筋痛症および他の障害を処置するためのプレガバリン誘導体
JP2006511624A (ja) * 2002-12-20 2006-04-06 ダイノジェン ファーマシューティカルズ， インコーポレイテッド α２δサブユニット・カルシウム・チャンネル調節因子を使用する無痛性膀胱障害を処置するための方法
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
BRPI0414343A (pt) * 2003-09-12 2006-11-07 Pfizer combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina
ES2373042T3 (es) * 2003-10-08 2012-01-30 Mallinckrodt Llc Solución de metilfenidato y procedimientos de administración y producción asociados.
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
EP1543831A1 (fr) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Composition de pregabaline
DE102004015752B4 (de) * 2004-03-31 2007-04-05 Christian-Albrechts-Universität Zu Kiel Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen
CN101039664A (zh) * 2004-10-14 2007-09-19 大金工业株式会社 气氛改变方法、用于该气氛改变方法的喷雾剂与喷雾装置
JP2009504613A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
JP2009504614A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2246044A1 (fr) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Solutions pédiatriques de bêta-bloquants
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2923694B1 (fr) * 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Solution pharmaceutique liquide orale de gabapentine
CN104940930A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫药物口服乳剂及其制备方法
WO2018167628A1 (fr) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Composition pharmaceutique de suspension orale d'agents immunosuppresseurs
WO2019038584A1 (fr) 2017-08-19 2019-02-28 Ftf Pharma Private Limited Composition pharmaceutique orale comprenant du zonisamide et son procédé de préparation
WO2019186515A1 (fr) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Compositions pharmaceutiques liquides de médicaments anti-épileptiques
EP3836898A2 (fr) 2018-08-18 2021-06-23 FTF Pharma Private Limited Suspension pharmaceutique pour forme galénique orale
WO2020039264A2 (fr) * 2018-08-18 2020-02-27 Ftf Pharma Private Limited Suspension pharmaceutique chimiothérapeutique pour forme galénique orale
CA3131336A1 (fr) 2019-03-26 2020-10-01 Mirja Huhtinen Formulations de pregabaline et leur utilisation
WO2022168968A1 (fr) * 2021-02-05 2022-08-11 学校法人近畿大学 Agent pour prévenir ou soulager la neuropathie périphérique
WO2023034269A1 (fr) * 2021-08-31 2023-03-09 Avion Pharmaceuticals, Llc Poudre de gabapentine stable

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
SI1077692T1 (en) * 1998-05-15 2004-10-31 Warner-Lambert Company Llc Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same
EP1337271B1 (fr) * 2000-11-30 2004-11-03 Pfizer Products Inc. Combinaison d'agonistes gaba et d'inhibiteurs de la sorbitol-deshydrogenase (sdi)

Also Published As

Publication number Publication date
AU2002258026B2 (en) 2007-08-02
KR100582963B1 (ko) 2006-05-24
HRP20030833A2 (en) 2004-08-31
SK286227B6 (sk) 2008-05-06
EP1395242A1 (fr) 2004-03-10
PL366384A1 (en) 2005-01-24
CA2446574A1 (fr) 2002-11-28
US20020198261A1 (en) 2002-12-26
DE60213592T2 (de) 2007-08-09
NO20035200D0 (no) 2003-11-24
CR7150A (es) 2004-02-23
WO2002094220A1 (fr) 2002-11-28
HUP0401366A2 (hu) 2004-11-29
US20040072904A1 (en) 2004-04-15
IS2428B (is) 2008-10-15
EA008087B1 (ru) 2007-02-27
MY128615A (en) 2007-02-28
EP1395242B1 (fr) 2006-08-02
CZ20033066A3 (cs) 2004-08-18
CY1105147T1 (el) 2010-03-03
SK14112003A3 (sk) 2004-08-03
PE20030087A1 (es) 2003-02-14
AP1815A (en) 2008-01-04
DOP2002000403A (es) 2002-11-30
MA27026A1 (fr) 2004-12-20
ATE334656T1 (de) 2006-08-15
NZ529173A (en) 2005-07-29
AP2003002907A0 (en) 2003-12-31
ZA200308393B (en) 2005-04-26
RS87203A (en) 2006-10-27
KR20040003006A (ko) 2004-01-07
EG24078A (en) 2008-05-11
SI1395242T1 (en) 2006-10-31
AR033922A1 (es) 2004-01-07
IS6986A (is) 2003-10-09
CZ299755B6 (cs) 2008-11-12
IL158359A0 (en) 2004-05-12
BR0209973A (pt) 2004-04-06
NO20035200L (no) 2003-11-24
GEP20053620B (en) 2005-09-26
EA200301152A1 (ru) 2004-04-29
EE200300587A (et) 2004-02-16
OA12604A (en) 2006-06-08
BG108376A (bg) 2005-04-30
MXPA03009392A (es) 2004-01-29
PT1395242E (pt) 2006-11-30
ES2265040T3 (es) 2007-02-01
SV2003001053A (es) 2003-03-18
US7256216B2 (en) 2007-08-14
JP2004534764A (ja) 2004-11-18
CN100346779C (zh) 2007-11-07
DE60213592D1 (de) 2006-09-14
HK1062646A1 (en) 2004-11-19
PA8545901A1 (es) 2003-09-05
CA2446574C (fr) 2008-04-01
CN1509165A (zh) 2004-06-30
DK1395242T3 (da) 2006-10-30

Similar Documents

Publication Publication Date Title
HRP20030833B1 (en) Liquid pharmaceutical composition
ATE276735T1 (de) Zusammensetzung zur hautdesinfektion
HN2002000154A (es) Azaindoles
BR0013157A (pt) Composições farmacêuticas e nutricionais contendo ácidos graxos essenciais e agentes de abaixamento da homocisteìna
ATE409512T1 (de) Verbindungen zur kontrollierten freigabe aktiver molekülen
DE69920017D1 (de) Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen
RS54573B1 (en) MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
CR8107A (es) Fungicida
MY133174A (en) Dipeptide nitriles
HUP0102160A2 (hu) Alfa-keto-enamin-származékok alkalmazása alkotórészként
ME00671B (fr) Nouvelle composition pharmaceutique
RS51808B (en) PROCEDURES FOR THE APPLICATION OF AMINOPYRIDINE COMPOUNDS WITH LONG TERM RELEASE
ES2193874B1 (es) Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas.
CY1107196T1 (el) Υποκατεστημενα παραγωγα 2,4-διϋδρο-πυρρολο (3,4-β) -κινολιν-9-ονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
ATE306925T1 (de) Minoxidil enthaltende zubereitung
ATE515252T1 (de) Pseudokörpergeruchszusammensetzung
ATE359279T1 (de) Moschus-geruchsstoffe
DE60311830D1 (de) Wasserlöslicher behälter
PL1553162T5 (pl) Toaletowe kostki
DE60209215D1 (de) Zusammensetzungen mit verbesserter farbstabilität die leucine enthalten
WO2002056840A3 (fr) Produit cosmetique et/ou pharmaceutique
ATE342880T1 (de) Aliphatische verbindungen als duftstoffe mit moschuscharakter
DE60105028D1 (de) Ruthenium (ii) verbindungen in der krebsbehandlung
DE602004029459D1 (de) Verbessertes reinigungsmittel
MXPA04005308A (es) Compuestos organicos.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080402

Year of fee payment: 7

PBON Lapse due to non-payment of renewal fee

Effective date: 20090430